(37 interviews) and urinary and sexual outcome measures were similar across treatments. Notably, only 75% of ThuVARP patients underwent their allocation versus 98% for TURP, mostly due to ThuVARP equipment failure (18/51). Prostate cancer was detected incidentally less frequently after ThuVARP (13% vs. 5%, odds ratio 0.35, 95% CI 0.16 to 0.75) in an exploratory analysis. The ThuVARP operation took 20 minutes on average longer than TURP. Costs were similar at £4,185 for TURP and £67 higher for ThuVARP (95% CI -£353 to £486).
INTRODUCTION AND OBJECTIVES: Aquablation offers effective robot-executed tissue removal for the treatment of benign prostatic obstruction. Aim of this prospective evaluation was to compare the efficacy of Aquablation to TUR-P, PVP and laser enucleation in a real-life setting.
METHODS: In this multi-institutional prospective study, all patients undergoing Aquablation therapy in a defined time interval have been evaluated for perioperative course, morbidity and symptom relief after three month and compared to a consecutive cohort of the patients treated with the above mentioned surgeries in the same time interval.
RESULTS: 150 consecutive patients underwent Aquablation and have been compared to a consecutive cohort of patients undergoing laser enucleation (n:150), PVP (n:150) and TUR-P (n:86) during the same time. Outcome data and morbidity is displayed in Table 1 METHODS: Longitudinal sexual function data from the Rezum RCT was compared to results of MTOPS trial arms; monotherapy with doxazosin or finasteride, or combination drugs in subjects determined to be sexually active at baseline. Sexual function was evaluated using the International Index of Erectile Function (Rezum) and Brief Male Sexual Function Inventory (MTOPS); domains common to both questionnairessexual desire (SD), erectile function (EF), ejaculatory function (EjD) and overall sexual satisfaction were assessed at 1, 2, and 3-years. Item Response Theory (IRT) modeling further assessed these two questionnaires using a graded response model to determine whether both instruments were appropriately measuring the intended and similar aspects across all items within each sexual function domain. (N[310) . The IRT model analysis confirmed significant discrimination between the SF domains to validly assess longitudinal changes in outcomes in both trials. With continued daily drug use men experienced significant worsening of SD, EF and EjD with finasteride and combination drug therapy, and reduced SD and EF with doxazosin (p 0.004). Thermal therapy was not associated with significant mean negative changes in SF throughout 3 years after treatment.
RESULTS: Subjects treated: Rezum (N[86), doxazosin (N[301), finasteride (N[319), and combination of both drugs
CONCLUSIONS: The single water vapor thermal therapy procedure had no deleterious effect on four sexual function domains compared with appreciable worsening of SF after long-term mono-or combination drug use. This minimally invasive treatment may be a superior option for patients with moderate-to-severe LUTS unwilling to compromise sexual function. 
